

Form 144

FORM 144

NOTICE OF PROPOSED SALE OF SECURITIES
PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

144: Filer Information

Filer CIK 0001668085
Filer CCC XXXXXXXXX
Is this a LIVE or TEST Filing? LIVE TEST

Submission Contact Information

Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer Tenaya Therapeutics, Inc.
SEC File Number 001-40656
Address of Issuer 171 OYSTER POINT BLVD., SUITE 500
SOUTH SAN FRANCISCO
CALIFORNIA
94080
Phone 415-865-2066
Name of Person for Whose Account the Securities are To Be Sold COLUMN GROUP III-A, LP
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer 10% Stockholder

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	BTIG, LLC 350 Bush Street, 9th floor San Francisco CA 94104	1060727	596552.86	213744535	02/25/2026	NASDAQ GS

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from	Is this	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
--------------------	-------------------	-----------------------------------	---------------------	---------	---------------------	-------------------------------	-----------------	---------------------

		Whom Acquired	a Gift?		
Common	08/30/2019 Series B financing	Tenaya Therapeutics	<input type="checkbox"/>	177927	08/30/2019 Cash
Common	12/20/2018 Series A financing	Tenaya Therapeutics	<input type="checkbox"/>	313640	12/20/2018 Cash
Common	03/30/2020 Series B financing	Tenaya Therapeutics	<input type="checkbox"/>	177927	03/30/2020 Cash
Common	08/25/2020 Series B financing	Tenaya Therapeutics	<input type="checkbox"/>	177927	08/25/2020 Cash
Common	12/17/2020 Series B financing	Tenaya Therapeutics	<input type="checkbox"/>	213306	12/17/2020 Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
COLUMN GROUP III-A, LP 1 Letterman Drive Suite DM-900 San Francisco CA 94129	Common	02/10/2026	182295	148770.95
COLUMN GROUP III-A, LP 1 Letterman Drive, Suite DM-900 San Francisco CA 94129	Common	02/11/2026	2151458	1464712.61
COLUMN GROUP III-A, LP 1 Letterman Drive, Suite DM-900 San Francisco CA 94129	Common	02/20/2026	277769	170800.16
COLUMN GROUP III-A, LP 1 Letterman Drive, Suite DM-900 San Francisco CA 94129	Common	02/23/2026	162291	96920.19
COLUMN GROUP III-A, LP 1 Letterman Drive, Suite DM-900 San Francisco CA 94129	Common	02/24/2026	349212	214870.14

144: Remarks and Signature

Remarks

Date of Notice 02/25/2026

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature James Evangelista

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)